136992-21-7

Basic information

• Product Name: (R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE
• Synonyms: (R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE;(R)-N-Boc-2-(2-hydroxyethyl)morpholine;(R)-2-(2-Hydroxyethyl)-4-morpholinecarboxylic acid tert-butyl ester;(R)-2-(2-Hydroxyethyl)-4-morpholinecarboxylic acid
• CAS NO: 136992-21-7
• Molecular Formula: C11H21NO4
• Molecular Weight: 231.29
• Mol File: 136992-21-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 336℃
• Flash Point: 157℃
• Appearance: /
• Density: 1.097
• Vapor Pressure: 8.15E-06mmHg at 25°C
• Refractive Index: 1.474
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE(136992-21-7)
• EPA Substance Registry System: (R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE(136992-21-7)

Safety Data

• Hazardous Substances Data: 136992-21-7(Hazardous Substances Data)

Usage

General Description

(R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE is a chemical compound with the molecular formula C14H25NO5. It is a morpholine derivative that is commonly used as a pharmaceutical intermediate. (R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE is a chiral molecule, with the (R)-enantiomer being the active form. It is often utilized in the synthesis of various pharmaceuticals and can also be used as a building block for the development of new drugs. Additionally, (R)-TERT-BUTYL-2-(2-HYDROXYETHYL)MORPHOLINE-4-CARBOXYLATE has potential applications in the field of organic chemistry and drug discovery due to its unique chemical structure and properties.

InChI:InChI=1/C11H21NO4/c1-11(2,3)16-10(14)12-5-7-15-9(8-12)4-6-13/h9,13H,4-8H2,1-3H3/t9-/m1/s1

Upstream product

• 766539-28-0 2-(4-(tert-butoxycarbonyl)morpholin-2-yl)acetic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 112887-43-1 2-(2-hydroxyethyl)-4-benzylmorpholine 
• 503601-25-0 (±)-ethyl 2-(morpholin-2-yl)acetate 
• 73933-19-4 ethyl 4-(phenylmethyl)-2-morpholineacetate 
• 132995-76-7 (2-hydroxyethyl)-morpholine 

Downstream Products

• 1033219-23-6 WYE-114152 
• 1033219-19-0 1-(3-methoxyphenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-02-1 1-(4-fluorophenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-08-7 1-(2,4-difluorophenyl)-3-{2-[(2R)-morpholin-2-yl]ethyl}-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033219-15-6 1-{2-[(2R)-morpholin-2-yl]ethyl}-3-(2,4,6-trifluorophenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-81-9 4-fluoro-1-(2-fluorophenyl)-3-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-83-1 5-fluoro-1-(2-fluorophenyl)-3-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-86-4 5-fluoro-3-(2-fluorophenyl)-1-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1334315-89-7 4-fluoro-3-(2-fluorophenyl)-1-(2-morpholin-2-ylethyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033218-92-6 1-(2-morpholin-2-ylethyl)-3-phenyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033218-96-0 1-{2-[(2R)-morpholin-2-yl]ethyl}-3-phenyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1033218-94-8 1-{2-[(2S)-morpholin-2-yl]ethyl}-3-phenyl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide 
• 1257853-70-5 tert-butyl 2-(2-oxoethyl)morpholine-4-carboxylate 
• 1398495-52-7 4-((2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)methyl)benzoic acid 

Relevant articles and documents

PYRIDYL DERIVATIVES AS BROMODOMAIN INHIBITORS

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

SUBSTITUTED MORPHOLINES AS MODULATORS FOR THE CALCIUM SENSING RECEPTOR

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of calcium sensing (CaSR) receptors of Formula (I).

Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152)

Sequential modification of the previously identified 4-[3-aryl-2,2-dioxido- 2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols led to the identification of a new series of 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro- 2,1,3-benzothiadiazole 2,2-dioxides that are potent and selective inhibitors of the norepinephrine transporter over both the serotonin and dopamine transporters. One representative compound 10b (WYE-114152) had low nanomolar hNET potency (IC50 = 15 nM) and good selectivity for hNET over hSERT (>430-fold) and hDAT (>548-fold). 10b was additionally bioavailable following oral dosing and demonstrated efficacy in rat models of acute, inflammatory, and neuropathic pain.